On November 13, 2020 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, reported that it will be announcing its results for the third quarter 2020 on Tuesday 17 November 2020 (Press release, BerGenBio, NOV 13, 2020, View Source [SID1234570916]). A webcast presentation by BerGenBio’s senior management team will take place at 10:00 am CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.

The third quarter report and presentation will be available on the Company’s website in the Investors/Financial Reports section from 7:00 am CET the same day.